ATE464905T1 - Phosphattransporthemmer - Google Patents

Phosphattransporthemmer

Info

Publication number: ATE464905T1
Authority: AT; Austria
Prior art keywords: phosphate transport; transport inhibitors; lower alkyl; substituted; alkyl group
Prior art date: 2001-12-26

Application number

AT06077276T

Other languages

English (en)

Inventor

Stephen Randall Holmes-Farley

Cecilia M Bastos

Andrew T Papoulis

Thomas H Jozefiak

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-26

Filing date

2002-12-24

Publication date

2010-05-15

2002-12-24 Application filed by Genzyme Corp filed Critical Genzyme Corp

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE464905T1 publication Critical patent/ATE464905T1/de

Links

229910019142 PO4 Inorganic materials 0.000 title abstract 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 3
239000010452 phosphate Substances 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
125000005415 substituted alkoxy group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Furan Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT06077276T 2001-12-26 2002-12-24 Phosphattransporthemmer ATE464905T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34466001P	2001-12-26	2001-12-26
US37164902P	2002-04-10	2002-04-10

Publications (1)

Publication Number	Publication Date
ATE464905T1 true ATE464905T1 (de)	2010-05-15

Family

ID=26994039

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02806234T ATE362360T1 (de)	2001-12-26	2002-12-24	Hemmer des phosphattransports
AT06077276T ATE464905T1 (de)	2001-12-26	2002-12-24	Phosphattransporthemmer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT02806234T ATE362360T1 (de)	2001-12-26	2002-12-24	Hemmer des phosphattransports

Country Status (7)

Country	Link
US (2)	US7119120B2 (de)
EP (2)	EP1465638B1 (de)
JP (2)	JP4610900B2 (de)
AT (2)	ATE362360T1 (de)
AU (1)	AU2002367396A1 (de)
DE (2)	DE60220188T2 (de)
WO (1)	WO2003057225A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119120B2 (en) *	2001-12-26	2006-10-10	Genzyme Corporation	Phosphate transport inhibitors
US7119112B2 (en) *	2002-02-28	2006-10-10	Icagen, Inc.	Sulfonamides as potassium channel blockers
US20060083791A1 (en)	2002-05-24	2006-04-20	Moerck Rudi E	Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) *	2002-05-24	2004-08-19	Moerck Rudi E.	Rare earth metal compounds methods of making, and methods of using the same
EP1537075B1 (de) *	2002-09-05	2009-07-01	Neurosearch A/S	Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
EP1398029A1 (de) *	2002-09-10	2004-03-17	LION Bioscience AG	3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US7491718B2 (en) *	2002-10-08	2009-02-17	Abbott Laboratories	Sulfonamides having antiangiogenic and anticancer activity
US7220406B2 (en)	2002-10-22	2007-05-22	Genzyme Corporation	Method for promoting bone formation
DE10257357A1 (de) *	2002-12-09	2004-06-24	Bayer Ag	Fluorhaltige Benzaldehyde
ES2390057T3 (es) *	2004-04-20	2012-11-06	Amgen Inc.	Arilsulfonilamidas y usos como hidroxiesteroide deshidrogenasa
AU2005295609A1 (en) *	2004-10-15	2006-04-27	Spectrum Pharmaceuticals, Inc.	Phosphate binder with reduced pill burden
TW200637539A (en) *	2005-01-20	2006-11-01	Shionogi & Co	CTGF inhibitors
JP2009504779A (ja) *	2005-08-17	2009-02-05	アルテアナノインコーポレイテッド	家畜における慢性腎不全及びその他の病気の治療：組成物及び方法
JP2009504781A (ja) *	2005-08-17	2009-02-05	アルテアナノインコーポレイテッド	家畜における高リン血症：治療のための組成物、及び治療方法
DE102005044156A1 (de) *	2005-09-15	2007-03-29	Riemser Arzneimittel Ag	Substituierte Acetophenonderivate
GB0526255D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
GB0526252D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
WO2008005217A2 (en) *	2006-07-05	2008-01-10	Genzyme Corporation	Iron(ii)-containing treatments for hyperphosphatemia
WO2009017863A2 (en)	2007-05-08	2009-02-05	Burnham Institute For Medical Research	Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US7776877B2 (en)	2007-06-22	2010-08-17	Chemocentryx, Inc.	N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
JP2011523655A (ja) *	2008-06-03	2011-08-18	フレセニウスメディカルケアドイッチュランドゲーエムベーハー	ガンマセクレターゼモジュレータを含む医薬組成物
WO2010000372A2 (en) *	2008-06-09	2010-01-07	Ludwig-Maximilians-Universität München	New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
MX2011000051A (es) *	2008-07-07	2011-07-28	Fasgen Inc	Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos.
WO2018129556A1 (en)	2017-01-09	2018-07-12	Ardelyx, Inc.	Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20170091783A (ko)	2008-12-31	2017-08-09	알데릭스, 인코포레이티드	체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2010083613A1 (en)	2009-01-26	2010-07-29	Cytochroma Inc.	Phosphate management with small molecules
EP2486004B1 (de)	2009-10-09	2017-05-03	Zafgen, Inc.	Sulfonverbindungen zur verwendung in der behandlung von adipositas
WO2011109731A2 (en) *	2010-03-05	2011-09-09	Duophos	Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
KR101940207B1 (ko)	2010-05-12	2019-01-18	스펙트럼 파마슈티컬즈 인크	란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
EP2590656B1 (de)	2010-07-07	2017-11-15	Ardelyx, Inc.	Verbindungen und verfahren zur hemmung eines phosphattransports
JP5827327B2 (ja)	2010-07-07	2015-12-02	アーデリクス，インコーポレーテッド	リン酸輸送を阻害する化合物及び方法
JP5827328B2 (ja) *	2010-07-07	2015-12-02	アーデリクス，インコーポレーテッド	リン酸輸送を阻害する化合物及び方法
JP5827326B2 (ja) *	2010-07-07	2015-12-02	アーデリクス，インコーポレーテッド	リン酸輸送を阻害する化合物及び方法
CN103249735B (zh)	2010-07-22	2016-04-06	扎夫根股份有限公司	三环化合物及其制备和使用方法
KR20140006888A (ko)	2011-01-26	2014-01-16	자프겐 인크.	테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
BR112013028666A2 (pt)	2011-05-06	2017-08-08	Zafgen Inc	compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
AU2012253759B2 (en)	2011-05-06	2016-01-21	Zafgen Inc.	Tricyclic sulfonamide compounds and methods of making and using same
CA2835261C (en)	2011-05-06	2019-06-04	Zafgen, Inc.	Partially saturated tricyclic compounds and methods of making and using same
MX2014008706A (es)	2012-01-18	2015-03-05	Zafgen Inc	Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
JP2015509102A (ja)	2012-01-18	2015-03-26	ザフゲン，インコーポレイテッド	三環式スルホン化合物並びにその作製および使用方法
US10376481B2 (en)	2012-08-21	2019-08-13	Ardelyx, Inc.	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013304812B2 (en)	2012-08-21	2016-06-09	Ardelyx, Inc.	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2015536981A (ja)	2012-11-05	2015-12-24	ザフゲン，インコーポレイテッド	三環式化合物ならびにその製造および使用方法
NZ707773A (en)	2012-11-05	2019-05-31	Zafgen Inc	Methods of treating liver diseases
BR112015010223A2 (pt)	2012-11-05	2017-07-11	Zafgen Inc	compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
SMT201900386T1 (it)	2013-04-12	2019-09-09	Ardelyx Inc	Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
CN103467452B (zh) *	2013-09-11	2015-11-18	陕西理工学院	一种苯甲酰胺类化合物及其应用
CN106008360B (zh) *	2016-08-11	2018-10-16	华南农业大学	一种对氨基苯磺酰咪唑及其制备方法
JOP20190080A1 (ar)	2016-10-14	2019-04-11	Bayer Pharma AG	مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3558992A4 (de)	2016-12-15	2020-12-02	ONO Pharmaceutical Co., Ltd.	Aktivator von trek (twik-assoziierten k+ kanälen)-kanälen
AU2018205400C1 (en)	2017-01-09	2026-01-15	Ardelyx, Inc.	Compounds useful for treating gastrointestinal tract disorders
JP2020505333A (ja)	2017-01-09	2020-02-20	アルデリックス，インコーポレイテッド	Ｎｈｅ媒介性アンチポートの阻害薬
WO2019028343A1 (en) *	2017-08-03	2019-02-07	Georgetown University	SMALL MOLECULE INHIBITORS OF SLC25A1
BR112020014561A2 (pt) *	2018-01-17	2020-12-08	Migal - Galilee Research Institute Ltd.	Nibidores inovadores da via metabólica da metionina
EP3740482A1 (de)	2018-01-17	2020-11-25	Migal Galilee Research Institute Ltd.	Neue inhibitoren des methionin-stoffwechselweges
WO2019179436A1 (zh) *	2018-03-20	2019-09-26	成都海创药业有限公司	一种酰胺类化合物及其在治疗癌症中的用途
WO2019232384A1 (en) *	2018-06-01	2019-12-05	Promega Corporation	Inhibitors of oplophorus luciferase-derived bioluminescent complexes
CN114026085A (zh)	2019-04-11	2022-02-08	安吉昂生物医药公司	(e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
WO2021041561A2 (en) *	2019-08-26	2021-03-04	Avantaggiati Mauria Laura	Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
WO2023219127A1 (ja) *	2022-05-11	2023-11-16	中外製薬株式会社	嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2227519T3 (es)	1992-07-28	2005-04-01	Aventis Pharma Limited	Inhibidores de c-amp-fosfodiesterasa.
EP0619116A3 (en)	1993-04-05	1994-11-23	Hoechst Japan	Use of synthetic retinoids for osteopathy.
US5667775A (en) *	1993-08-11	1997-09-16	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
US5496545A (en) *	1993-08-11	1996-03-05	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
NZ277556A (en)	1993-12-27	1997-06-24	Eisai Co Ltd	N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
CA2235481A1 (en)	1995-10-23	1997-05-01	Sean M. Kerwin	Compositions and methods for treating bone deficit conditions
TW523506B (en) *	1996-12-18	2003-03-11	Ono Pharmaceutical Co	Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CA2298824A1 (en)	1997-08-06	1999-02-18	Smithkline Beecham Corporation	Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
HUP0102782A3 (en)	1998-06-19	2002-12-28	Smithkline Beecham Corp	Salycilanilide as inhibitors of transcription factor nf-kb
JP3972163B2 (ja) *	1999-06-18	2007-09-05	株式会社大塚製薬工場	ホスホン酸ジエステル誘導体
CO5190714A1 (es)	1999-07-20	2002-08-29	Smithkline Beecham Corp	Inhibidores del transporte de fosfato
AU2001259354A1 (en)	2000-05-02	2001-11-12	Smith Kline Beecham Corporation	Phosphate transport inhibitors
KR20020093983A (ko)	2000-05-12	2002-12-16	스미스클라인 비참 코포레이션	포스페이트 수송 억제제
AU2002213048A1 (en) *	2000-10-05	2002-04-15	Smith Kline Beecham Corporation	Phosphate transport inhibitors
DE10121003A1 (de) *	2001-04-28	2002-12-19	Aventis Pharma Gmbh	Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119120B2 (en) *	2001-12-26	2006-10-10	Genzyme Corporation	Phosphate transport inhibitors

2002
- 2002-12-20 US US10/327,627 patent/US7119120B2/en not_active Expired - Lifetime
- 2002-12-24 DE DE60220188T patent/DE60220188T2/de not_active Expired - Lifetime
- 2002-12-24 AU AU2002367396A patent/AU2002367396A1/en not_active Abandoned
- 2002-12-24 AT AT02806234T patent/ATE362360T1/de not_active IP Right Cessation
- 2002-12-24 JP JP2003557583A patent/JP4610900B2/ja not_active Expired - Fee Related
- 2002-12-24 EP EP02806234A patent/EP1465638B1/de not_active Expired - Lifetime
- 2002-12-24 DE DE60236117T patent/DE60236117D1/de not_active Expired - Lifetime
- 2002-12-24 EP EP06077276A patent/EP1815860B1/de not_active Expired - Lifetime
- 2002-12-24 WO PCT/US2002/041481 patent/WO2003057225A2/en not_active Ceased
- 2002-12-24 AT AT06077276T patent/ATE464905T1/de not_active IP Right Cessation
2006
- 2006-07-19 US US11/489,286 patent/US20070021509A1/en not_active Abandoned
2010
- 2010-01-18 JP JP2010008273A patent/JP2010132674A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1815860A3 (de)	2007-11-21
WO2003057225A3 (en)	2004-04-08
US7119120B2 (en)	2006-10-10
ATE362360T1 (de)	2007-06-15
JP4610900B2 (ja)	2011-01-12
WO2003057225A2 (en)	2003-07-17
DE60220188D1 (de)	2007-06-28
DE60236117D1 (de)	2010-06-02
EP1465638A2 (de)	2004-10-13
JP2005514413A (ja)	2005-05-19
AU2002367396A1 (en)	2003-07-24
US20040019113A1 (en)	2004-01-29
EP1815860B1 (de)	2010-04-21
US20070021509A1 (en)	2007-01-25
EP1815860A2 (de)	2007-08-08
JP2010132674A (ja)	2010-06-17
EP1465638B1 (de)	2007-05-16
DE60220188T2 (de)	2008-01-24

Legal Events

Date	Code	Title	Description
2010-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60236117D1 (de)	2010-06-02	Phosphattransporthemmer
DK0931788T3 (da)	2002-11-25	Metalloproteasehæmmere
DE69221794D1 (de)	1997-10-02	3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
EA200000048A1 (ru)	2000-08-28	ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
EA199900591A1 (ru)	2000-08-28	АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
IT1290823B1 (it)	1998-12-11	Idrossifeniltriazine
EA200400361A1 (ru)	2004-08-26	Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
DK0771794T3 (da)	2006-09-11	Oxygenholdige heterocykliske forbindelser
PT1250340E (pt)	2005-04-29	Metodos e compostos para inibicao de mrp1
ATE384722T1 (de)	2008-02-15	Alkoxypyridinderivate
DK0618193T3 (da)	1999-06-28	Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
DE60111228D1 (de)	2005-07-07	Heteropolycyclische inhibitoren
DE69808099D1 (de)	2002-10-24	Substituierte 6-alkylphenanthridine
ATE67159T1 (de)	1991-09-15	Biozide zusammensetzung.
BR0311223A (pt)	2005-03-15	Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
NO970340D0 (no)	1997-01-27	Organiske forbindelser
EA200101230A1 (ru)	2002-06-27	Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
DE60223227D1 (de)	2007-12-13	BenzoÄbÄthiophenderivate und Verfahren zu deren Herstellung
DK0844241T3 (da)	2003-05-12	Inhibitor af narkotisk analgetisk afhængighed/resistensudvikling
UA26459C2 (uk)	1999-08-30	Іhгібітор впливу амілоїдhих білків
ATE430476T1 (de)	2009-05-15	Schlammbehandlung
AR247750A1 (es)	1995-03-31	Sistema inhibidor de polimerizacion y composicion estabilizada que lo comprende.
MXPA04002039A (es)	2004-06-07	Mezclas fungicidas.
DK0777471T3 (da)	2003-03-17	Inhibering af leukotrienbiosynese med urinstofderivater
MXPA03005556A (es)	2004-05-31	Derivados de 1,1-dioxo-1,2-benzotiacina-3-carboxamidas, metodo para prepararlos y composiciones farmaceuticas que los contienen.